CanSino Biologics proposes share incentives, capital reduction at EGM

CanSino Biologics Inc. has scheduled a first extraordinary general meeting for October 23, 2025, to vote on several key resolutions. Shareholders will consider adopting a 2025 A share incentive scheme, which includes the proposed issue of restricted shares, and its associated assessment management measures. The total number of restricted shares to be granted under this scheme is capped at 2,580,000, with a grant price of RMB41.20 per A share, representing approximately 1.04% of the company's total share capital.

Additionally, the company proposes to adopt a 2025 H share option scheme, which will allow for the grant of options to key management, including a conditional grant of 371,300 H share options to chairman Dr. Xuefeng Yu at an exercise price of HK$49.924 per H share. Both schemes incorporate performance targets for vesting over 2025-2027.

The EGM will also address the proposed cancellation of 406,098 repurchased A shares and a corresponding reduction in registered capital, aiming to decrease the total issued share capital from 247,449,899 shares to 247,043,801 shares.